Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 24, 2014- Selinexor Synergy with DNA Damage Inducing Treatments Provides Potential for Improved Clinical Outcomes -
NEWTON, Mass., Nov. 24, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of data describing its...
-
Nov 10, 2014- Reported Positive Phase 1 Clinical Data Demonstrating Early Signs of Activity for Selinexor in Several Solid Tumor Settings -
NEWTON, Mass., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the third quarter ended...
-
Nov 10, 2014
NEWTON, Mass., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the initiation of its Phase 2 study of...
-
Nov 6, 2014
NEWTON, Mass., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that clinical and pre-clinical data for its...
-
Nov 5, 2014
NEWTON, Mass., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today that Michael G. Kauffman, MD, PhD, Chief Executive...